BEIJING, Nov. 16,
2022 /PRNewswire/ -- Concord Medical Services
Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM),
a healthcare provider specialized in cancer treatment, research,
education and prevention by establishing proton centers and cancer
hospitals and operating an extensive network of radiotherapy and
diagnostic imaging centers in China, today announced the successful holding
of the Second Annual Academic Meeting (the "Meeting") jointly by
Shanghai Concord Cancer Center and The University of Texas MD Anderson Cancer Center ("MD
Anderson") on November 11 and
November 12, 2022.
With the theme of "Immuno-Oncology: Confronting the Whole Cancer
Continuum," the Meeting gathered a number of well-known oncologists
and scholars from China and
the United States to share their
cutting-edge academic achievements in various ways, to promote
academic communications and cooperation in oncology worldwide.
Five main topics were discussed during the Meeting, including
Grasping the Promise of Immuno-Oncology: Bench to Bedside,
Immunotherapy Approaches for Limited Disease – Prevention,
Early-Stage and Oligometastatic Disease, Emerging Cellular Therapy
Approaches, Diagnostic and Immunotherapy Approaches for Advanced
Cancer, and Nursing Management of Immunotherapy. 12 experts from MD
Anderson participated in the Meeting, including nine of which as
guest speakers and three as moderators and opening speakers.
Experts from medical institutions in China, such as Fudan University Shanghai
Cancer Center, Ruijin Hospital and
Renji Hospital, also exchanged new ideas, methods and technologies
in immuno-oncology diagnosis and healthcare during the Meeting.
Dr. Jianyu Yang, Chairman and
Chief Executive Officer of Concord Medical, commented, "I would
like to express my heartfelt thanks to the experts who spoke on and
participated in the Meeting. The Meeting also attracted nearly 100
experts and scholars from medical institutions in different
countries, such as Singapore,
Poland, Israel and South
Korea, to participate online, to jointly create an
international high-standard academic pageant with us." Dr. Yang
further emphasized that, "Concord Medical will continue to act as
an important channel in oncology-related communications between
China and the United States, and actively promote the
development of oncology. Taking Immuno-Oncology as the main topic,
the two-day Meeting discussed the research and application of the
latest therapeutic technology and highlighted the "borderless"
medical communications, with a view to ultimately benefiting the
MD Anderson is one of the best-known cancer treatment centers
globally and the largest cancer center in the United States. Since 2015, MD Anderson has
been providing the Company's medical institutions with
comprehensive consultation and support in various aspects,
including, among others, clinical practice development, cancer
center development, medical direction, physician and staff
training, as well as research, strategic and business support.
Leveraging years of strategic cooperation, MD Anderson and Shanghai
Concord Cancer Center successfully cohosted the First Annual
Academic Meeting in November
About Concord Medical
Concord Medical Services Holdings Limited is a healthcare
provider featuring a full cycle of premium oncology services
including cancer diagnosis, treatment, education and prevention.
The Company focuses on providing multidisciplinary cancer care in
all aspects of oncology healthcare services in its cancer hospitals
and equipping them with technologically advanced equipment such as
the state-of-the-art proton therapy system. The Company is striving
to improve the quality and accessibility of cancer care through its
network of self-owned cancer hospitals and clinics as well as
partnered hospitals across China.
For more information, please see
Safe Harbor Statement
This announcement contains forward-looking statements. These
forward-looking statements can be identified by words or phrases
such as "will," "expects," "anticipates," "future," "intends,"
"plans," "believes," "estimates" and similar expressions.
Forward-looking statements are inherently subject to uncertainties
and contingencies beyond the Company's control and based upon
premises with respect to future business decisions, which are
subject to change. A number of important factors could cause actual
results to differ materially from those contained in any
forward-looking statement. The Company does not undertake any
obligation to update any forward-looking statement, except as
required under applicable law.
SOURCE Concord Medical Services Holdings Limited